PubMed Trending Research Digest — July 29, 2026

Automated digest · 96 articles · 15 research areas · July 29, 2026

Overview

Across this week’s set of studies, a dominant theme is the growing use of mechanistic “systems” biology to connect upstream drivers to downstream clinical outcomes. Cancer papers repeatedly link metabolism, signaling, and immune escape—ranging from ADSL/fumarate-driven succination-dependent metastasis in TNBC, to UFMylation/DDRGK1 vulnerabilities in glioblastoma, to exosome-mediated drug resistance and immune evasion. In parallel, neurodegeneration work emphasizes immune and molecular propagation: complement activation during early synucleinopathy, microglial state complexity beyond binary models, and “seed” properties of soluble >150 kDa Aβ species that accelerate in vivo amyloidosis.

A second major thread is translational biomarker and endpoint development for earlier diagnosis and better stratification. Plasma phospho-tau panels help distinguish early-onset Alzheimer’s from frontotemporal dementia, while large-scale plasma proteomics provides scalable signatures across dementia subtypes. In neurodegenerative trials, blood NfL is increasingly used as an endpoint, and the literature is moving toward standardization. In oncology, proteogenomic and checkpoint-heterogeneity studies (e.g., B7-H family profiling in metastatic ccRCC) aim to refine prognosis and treatment response prediction, while imaging/pathology integration (e.g., TBSr with TRG) improves recurrence characterization after neoadjuvant therapy.

Finally, multiple studies highlight host-directed and immune-modulating strategies across infectious disease, inflammatory disease, and critical care. Viral fusion phenotypes (SARS-CoV-2 syncytia) are tied to interferon resistance, while host pathways such as ATRA–PPARγ signaling suppress hyperinflammation in SFTSV. In non-cancer immune contexts, endothelial NOD2 signaling shapes intestinal T-cell homeostasis, and macrophage NOD1/2–RIPK2 signaling contributes to adaptive resistance to cancer therapies. Together with several randomized trials and guideline updates (e.g., COPD biologic programs, RSV prophylaxis, perioperative immunonutrition, and pain-management recommendations), the overall picture is a field moving toward more targeted, mechanism-aligned interventions—supported by better biomarkers and more rigorous trial/endpoint frameworks.

---

Cancer metabolism & metastasis signaling

α-fluoro-β-alanine functions as a β-arrestin1-biased ligand of S1PR2 to upregulate DPD expression in cancer cells.

This work identified α-fluoro-β-alanine (FBAL), a catabolite of the chemotherapeutic 5-fluorouracil (5-FU), as a β-arrestin1-biased ligand of sphingosine 1-phosphate receptor 2 (S1PR2) and tested its effects in colorectal cancer cells. The key finding was that FBAL activates β-arrestin1-biased S1PR2 signaling to upregulate dihydropyrimidine dehydrogenase (DPD) via GRK6-mediated phosphorylation, driving 5-FU resistance. Clinically, this links a 5-FU metabolite to a specific GPCR signaling axis that could be targeted to overcome resistance.

Tan M, Shao H, Zhang X et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

Mitochondrial SLC25A46 Rewires Fatty Acid Oxidation to Promote Cell Proliferation and Ferroptosis Evasion in Ovarian Cancer by Stabilizing CACT.

This study investigated the role of the mitochondrial gene SLC25A46 in ovarian cancer (OC) by testing how SLC25A46 affects fatty acid oxidation, cell proliferation, and ferroptosis evasion through CACT stabilization and interaction with MARCHF5-related regulation. The key finding was that SLC25A46 is upregulated in OC, promotes tumor growth by increasing fatty acid oxidation–driven ATP and NADPH production, and helps evade ferroptosis by protecting CACT from MARCHF5-mediated effects. This is significant because it identifies an actionable metabolic vulnerability pathway (SLC25A46–CACT axis) that could be targeted to limit OC progression and ferroptosis resistance.

Gao Y, Hao J, Zhang X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Inhibition of the Metalloproteinase ADAMTS5 Suppresses Colorectal Cancer Metastasis via the PEDF/Wnt/β-Catenin Pathway.

This study investigated the role of the metalloproteinase ADAMTS5 in colorectal cancer (CRC) metastasis and the underlying PEDF/Wnt/β-catenin signaling pathway. It found that ADAMTS5 was upregulated in CRC tissues versus paracancerous tissues and that inhibiting ADAMTS5 suppressed CRC metastasis through modulation of the PEDF/Wnt/β-catenin axis. These findings suggest ADAMTS5 as a therapeutic target to limit metastatic progression in CRC via a defined signaling pathway.

Sun X, Zhang H, Hu Y et al. · Cancer medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression.

This study tested two small-molecule UFMylation inhibitors that target the UFMylation E3 ligase complex core protein DDRGK1—osimertinib (via a covalent mechanism) and CP-24 (non-covalent)—to reprogram tumor and immune microenvironments in glioblastoma models. It found that both compounds disrupt the DDRGK1–UFL1 interaction, globally suppress UFMylation, inhibit ER-phagy, and induce ER stress–linked effects that drive long-term glioblastoma regression. The results suggest DDRGK1/UFMylation as a druggable vulnerability that can reshape both tumor biology and antitumor immunity.

Tan P, Liu Z, Hu X et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Exosomes in cancer drug resistance: dual roles in therapy failure and emerging precision therapeutics.

This review explains how tumor-derived exosomes contribute to cancer drug resistance while also being leveraged for precision therapeutics, introducing the concept of an “exosome paradox.” The key finding is that exosomal cargo—including proteins such as P-gp and PD-L1, nucleic acids such as miR-21 and lncRNA H19, and other bioactive molecules—can activate pathways (e.g., PI3K/AKT and MAPK) and remodel the tumor microenvironment to promote therapy failure and immune evasion. This frames exosomes as both mechanistic drivers and therapeutic delivery targets, supporting development of exosome-based precision interventions.

Tegegne BA, Belew H, Teffera ZH et al. · Cancer cell international · (2026) · View on PubMed ↗ · Free PDF ↗

ADSL drives fumarate mediated scrib-rictor complex formation to promote metastasis dissemination in triple-negative breast cancer.

This study investigated how ADSL-driven fumarate production promotes SDC1-RICTOR (Scrib-Rictor) complex formation to drive metastasis dissemination in triple-negative breast cancer (TNBC) using untargeted metabolomics, chemoproteomic succination profiling, interaction assays, and in vivo metastasis models. The authors found that ADSL-mediated fumarate increases succination-dependent SDC1-RICTOR complex assembly, thereby enhancing metastatic dissemination. These findings identify a metabolism-to-metastasis signaling axis in TNBC and suggest that targeting ADSL/fumarate-dependent complex formation could be a therapeutic strategy to limit metastatic spread.

Fan Y, He X, Deng W et al. · Molecular cancer · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer immunotherapy & cell-based therapies

First CAR T-Cell Therapy Approved for Solid Tumors.

China studied the first approved solid-tumor CAR T-cell therapy, satricabtagene autoleucel (satri-cel), in patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer. In a phase II trial, satri-cel increased progression-free survival and overall survival. This approval is clinically significant because it provides early evidence that CAR T targeting claudin 18.2 can benefit solid tumors, while highlighting the need to improve efficacy and durability.

Cancer discovery · (2026) · View on PubMed ↗

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

A phase 1/2 clinical study evaluated IMC-C103C, a T cell receptor bispecific ImmTAC (MAGE-A4×CD3) targeting the MAGE-A4 cancer-testis antigen presented by HLA-A02:01, in advanced solid tumors. In HLA-A02:01+ patients receiving weekly intravenous infusions with step-up dosing, the trial assessed safety and preliminary anti-tumor activity using the mTPI-2 dose-escalation method alongside pharmacokinetics/pharmacodynamics and biomarker analyses. This establishes early clinical evidence for an HLA-restricted, antigen-specific T cell engager strategy against MAGE-A4-expressing malignancies.

Sweis RF, Melero I, Davar D et al. · Journal for immunotherapy of cancer · (2026) · View on PubMed ↗ · Free PDF ↗

Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.

This review studied next-generation immunotherapies beyond immune checkpoint blockade, focusing on T cell engagers (TCEs) and antibody-drug conjugates (ADCs) in cancer and immune-mediated inflammatory disorders. It concluded that TCEs can redirect cytotoxic T cells to kill targets independently of MHC restriction, while ADCs deliver cytotoxic payloads via receptor-mediated internalization, offering strategies to overcome resistance and improve autoimmune efficacy. These mechanistic insights are significant for guiding development and selection of more precise immunopharmacology approaches, including emerging targets such as the CD47/SIRPα axis.

Abdelaziz AM, Shokr MM · Biochemical pharmacology · (2026) · View on PubMed ↗

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

This preclinical study investigated a tri-specific NK cell engager designed to therapeutically target CD47 to inhibit multiple myeloma (MM). The key finding was that blocking CD47 signaling with the tri-specific engager enhances anti-tumor immune activity by countering CD47-mediated immune escape (SIRPα interaction that suppresses macrophage phagocytosis and NK activity). This is significant because it supports CD47-directed NK cell engager strategies as a potential approach to overcome resistance in MM patients who do not respond to standard therapies.

Sumankan R, Sungwan P, Boonsatit N et al. · Cancer immunology, immunotherapy : CII · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer biomarkers, prognostic modeling & response prediction

Incidence, risk factors and tumor spectrum of second primary cancers after gastric cancer: a multicenter cohort study with long-term follow-up.

This multicenter cohort study evaluated long-term incidence, risk factors, and tumor spectrum of second primary cancers (SPCs) in gastric cancer survivors who underwent curative-intent radical gastrectomy (2007–2021) in the MAGIS cohort. The key findings (partially truncated in the abstract) focus on quantifying SPC risk over follow-up and identifying clinical factors associated with SPC occurrence, along with detection patterns and stage distribution. Scientifically and clinically, the work supports improved long-term surveillance strategies after gastrectomy by clarifying which patients are at higher risk for SPCs.

Gao X, Han W, Lu L et al. · BMC medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Single-Cell Analysis of Residual Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Reveals TFAM-Mediated Immunoregulation in Dendritic Cells.

This study performed single-cell analysis of tumor microenvironments in 14 patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant immunochemotherapy (nICT) to identify cellular programs associated with treatment response. Using nonnegative matrix factorization (NMF), it found that a TFAM-mediated immunoregulation program in dendritic cells was linked to differential pathological tumor regression, including minimal/no regression groups. These findings suggest TFAM-driven dendritic-cell immune regulation as a mechanistic biomarker and potential target to improve nICT responsiveness in ESCC.

Chen L, Feng T, Zhou J et al. · Cancer research · (2026) · View on PubMed ↗

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

This analysis studied 310 patients with newly diagnosed multiple myeloma treated with upfront quadruplet therapy plus autologous stem cell transplantation (QUAD + ASCT) to redefine functional high-risk (FHR) multiple myeloma in the modern treatment era. The key finding was that the historical FHR definition (progression within 18 months with expected OS <2 years) may not optimally capture risk under QUAD + ASCT, prompting an updated definition based on observed progression events and outcomes (cutoff details truncated in the abstract). Clinically, redefining FHR in the QUAD + ASCT era can improve risk stratification and guide subsequent therapy intensity.

Ravi G, Dhakal B, Callander NS et al. · Cancer · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Immune checkpoint profiling of B7-H proteins predicts survival and treatment response in metastatic clear cell renal cell carcinoma.

This retrospective cohort study analyzed primary tumor specimens from 145 patients with metastatic clear cell renal cell carcinoma (ccRCC) to determine whether immune checkpoint B7-H family proteins (B7-H3, B7-H4, B7-H5, B7-H7) predict survival and treatment response. Immunohistochemistry showed marked intratumoral heterogeneity with compartmentalized expression patterns, and the study found that B7-H protein immune checkpoint profiling was associated with patient survival and treatment response (specific associations truncated in the abstract). Clinically, these biomarkers could help stratify metastatic ccRCC patients for prognosis and potential immunotherapy responsiveness.

Emaldi M, Rey-Iborra E, Mosteiro L et al. · The journal of pathology. Clinical research · (2026) · View on PubMed ↗ · Free PDF ↗

Anatomical and Histologic Response to Neoadjuvant Therapy: Recurrence Patterns Among Poor Responders. A Multi-institutional Observational Cohort Study.

This multi-institutional observational cohort study evaluated colorectal liver metastases (CRLM) patients undergoing curative hepatectomy after neoadjuvant therapy, integrating anatomical response using the Tumor Burden Score ratio (TBSr) with histologic response using Tumor Regression Grade (TRG). It found that combining TBSr and TRG better characterized recurrence patterns among poor responders than either macroscopic or histologic assessment alone. Clinically, this could improve post-hepatectomy risk stratification and surveillance strategies for CRLM patients treated with neoadjuvant therapy.

Baldo A, Akabane M, Elemosho A et al. · Annals of surgery · (2026) · View on PubMed ↗

---

Cancer genomics, proteomics & molecular mechanisms

Mechanism of actin thin filament pointed-end elongation by leiomodin.

This mechanistic study investigated how leiomodin (Lmod), particularly leiomodin-2 (Lmod2), promotes actin thin filament pointed-end elongation in striated muscle systems where actin length is uniform and subunit exchange occurs mainly at the pointed end. The key finding is that Lmod acts as an additional regulator of pointed-end actin dynamics, complementing known roles of nebulin (molecular ruler) and the capping proteins CapZ and tropomodulin (Tmod). This is significant for understanding the molecular control of sarcomere assembly and stability, with implications for muscle function and disease.

Brotzman SB, Palmer NJ, Boczkowska M et al. · Nature communications · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Mitochondrial-derived vesicles drive budding-type fission of damaged lysosomes.

Researchers studied lysosomal renewal under hypoxia-reoxygenation stress and identified a budding-type fission (B-fission) pathway that restores lysosomal function by generating small functional lysosomes. They found that damaged lysosomes form membrane buds that undergo scission independently of autophagic lysosome reformation, and that mitochondrial-derived vesicles (MDVs) deliver the fission adaptor MFF to lysosomes to recruit DRP1. This is significant because it reveals a new, mitochondria-linked mechanism for maintaining lysosomal integrity during stress.

Luo Y, Yu J, Li Z et al. · Nature cell biology · (2026) · 2 citations · View on PubMed ↗

Promoter strength and position govern promoter competition through transcript-dependent insulation.

This study investigated how promoter strength and genomic position govern promoter competition via transcript-dependent insulation at the Sox2 locus by inserting diverse promoters into defined genomic sites. The key finding is that the reduction in endogenous Sox2 transcription correlates with inserted promoter strength, and that competition requires transcription from the inserted promoter, with longer transcripts producing more competition. Scientifically, it shows that an active promoter/transcriptional unit can function as an insulator, improving understanding of gene regulation in development and disease.

Koska M, Nagano M, Swigut T et al. · Nature genetics · (2026) · View on PubMed ↗

A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.

This mechanistic cancer study created lysine acetyltransferase (KAT)-based chemically induced proximity (CIP) molecules (KAT-TCIPs) to link p300/CBP to oncogene-repressed cell-death networks in diffuse large B cell lymphoma. It found that KAT-TCIPs reprogram the epigenome to activate apoptosis by redirecting p300/CBP to counteract BCL6-driven repression. This is significant because it provides a small-molecule, proximity-based approach to induce selective death of malignant B cells and potentially reduce relapse risk.

Nix MN, Gourisankar S, Bowman KJ et al. · Cell · (2026) · View on PubMed ↗

Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy.

This structural proteomics study used PhIX-MS (photo-induced in situ crosslinking-mass spectrometry) combined with cryo-electron microscopy to map transient interactors at native proteasomes. It resolved the dynamic thioredoxin-like domain of the redox sensor TXNL1 at the proteasome regulatory particle (RP), including its positioning near RPN2/PSMD1 and RPN13/ADRM1, and characterized RP structures bound to TXNL1 without the proteolytic core particle. These findings are significant for understanding how redox sensing and low-affinity interactions regulate substrate reduction and proteolysis in cells.

Lee K, Negi H, Chen X et al. · Molecular cell · (2026) · View on PubMed ↗

RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity.

This study investigated how the RNA exonuclease REXO4 regulates tumor-associated R-loop biology by resolving m6A-marked R-loops in human cells and assessing immune consequences. It found that REXO4 resolves RNA-DNA hybrids via 3’-5’ exonucleolytic cleavage of the RNA strand, that m6A promotes REXO4 localization to R-loops, and that REXO4 loss increases DNA damage, triggers interferon responses, and enhances tumor immune infiltration. The results are significant because they link m6A-dependent R-loop homeostasis to anti-tumor immunity and identify REXO4 as a potential therapeutic lever.

Zhang J, Bao K, Hou Y et al. · Molecular cell · (2026) · View on PubMed ↗ · Free PDF ↗

The orchestration of ciliary opus: Interplay of signalling molecules, GTPases, and trafficking machinery.

This review studied how primary cilia are assembled and maintained through coordinated signaling, small GTPases, and trafficking machinery. It concluded that intraflagellar transport (IFT) trains (kinesin-2 and dynein-2 motors), the BBSome coat complex, and ciliary lipid composition work together to control receptor and signaling component entry/exit, with secondary messengers such as cAMP and Ca2+ coordinating these processes. This is significant for understanding how ciliary dysfunction can drive disease and for identifying molecular targets within the ciliary trafficking-signaling network.

Piyush R, Giri P, Shinde SR · Current opinion in cell biology · (2026) · View on PubMed ↗

Ligand regulation and function of preformed EGFR dimers.

This study used cryo-electron microscopy to determine the structural basis of ligand regulation and function of preformed epidermal growth factor receptor (EGFR) dimers in the context of receptor tyrosine kinase activation. The key finding was a detailed structural view showing how preformed EGFR dimers are organized and regulated, refining the classic ligand-induced dimerization model. Scientifically, this provides a mechanistic framework for how EGFR signaling can be modulated at the dimer level, informing therapeutic strategies targeting EGFR in cancer.

Zuo Y, Schwartz HT, Walker K et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗ · Free PDF ↗

A genome-wide functional analysis of conserved intronic regions reveals essential roles for speckle-associated retained introns.

This genome-wide functional study used a dual CRISPR-Cas editing strategy to delete 2,600 conserved human intronic regions associated with intron retention, focusing on speckle-associated retained introns in human cells. The key finding was that a subset of these conserved “fitness” intronic sequences affects cell growth by altering intron retention and host gene expression, with nuclear speckle-associated retained introns in FNBP4 and DDX5 producing downstream effects. Scientifically, it establishes conserved retained introns as functional regulatory elements essential for normal cellular fitness and gene regulation.

Farhangmehr S, Braunschweig U, Wu M et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes.

This study developed and tested targeted mRNA delivery using bispecific antibody–lipid nanoparticle complexes (TbsAb-LNPs) designed to enhance extrahepatic, tissue- and cell-specific uptake beyond conventional lipid nanoparticles. The key finding was that the bispecific antibody targeting strategy enables targeted LNP uptake modeling in vitro to better predict in vivo delivery performance (full experimental outcomes truncated in the abstract). Scientifically, this platform advances targeted RNA therapeutics by improving the specificity of LNP delivery for individualized, extrahepatic applications.

Hickey JC, Roach T, Cassaidy B et al. · Molecular pharmaceutics · (2026) · View on PubMed ↗

Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome system.

This study used harmonized pan-cancer proteogenomic data from up to 11 CPTAC cohorts to interrogate how somatic mutations remodel the ubiquitin-proteasome system (UPS) at the protein level, focusing on UPS protein dysregulation, prognostic associations, and mutation-driven remodeling (notably TP53 loss). It found that mRNA levels poorly predict UPS protein abundance, that a recurrent set of E3 ligases is dysregulated across cancers, and that somatic mutations generate coherent UPS protein quantitative trait locus (pQTL) signatures, with case studies including UBR5 and TRIM28. These findings support mutation-informed, proteome-level targeting of UPS components as a route to improve prognostic stratification and therapeutic design in cancer.

González-Robles TJ, Khan M, Sastourné P et al. · Cell death and differentiation · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

RNA modifications in cancer: regulators of tumor evolution and therapeutic response.

This review summarizes how RNA modifications (including m6A, m1A, m5C, m7G, pseudouridine, and A-to-I editing) regulate cancer evolution and therapeutic response by acting through epitranscriptomic “writers,” “readers,” and “erasers.” The key finding is that dysregulated RNA modification networks control transcript stability and translation, thereby shaping tumor evolution and sensitivity or resistance to therapy. This provides a mechanistic framework for developing RNA-modification-targeted biomarkers and treatments across cancer types.

Gu X, He Y, Xu Z et al. · Molecular cancer · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer therapeutics trials & treatment strategies

Immune-Enhancing Nutrition and Outcomes After Radical Cystectomy: A Randomized Clinical Trial.

This multicenter, randomized, double-blind phase 3 clinical trial (SWOG S1600) studied perioperative specialized immunonutrition versus standard oral nutrition support in adults undergoing radical cystectomy for bladder cancer. The key finding was that immune-enhancing nutrition improved postoperative outcomes by reducing 30-day complications compared with standard nutrition support. Clinically, it supports using targeted perioperative immunonutrition to lower morbidity in patients undergoing radical cystectomy.

Hamilton-Reeves JM, Unger JM, Holzbeierlein JM et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.

This review summarized precision medicine strategies in advanced/metastatic pancreatic cancer, focusing on targeting mutant KRAS and emerging therapeutic approaches beyond KRAS. The key finding was that the advent of KRAS inhibitors has expanded the theoretical eligibility for targeted therapeutics, and trial results such as RASolute 302 demonstrate clinically meaningful activity of RAS inhibition in metastatic pancreatic cancer. This is significant because it frames how KRAS-directed therapies may improve outcomes in a previously hard-to-treat population and guides future biomarker-driven treatment development.

Schürmann H, Park W, O’Kane GM et al. · Targeted oncology · (2026) · View on PubMed ↗ · Free PDF ↗

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B).

This phase II again study evaluated abemaciclib rechallenge in hormone receptor-positive, HER2-negative metastatic breast cancer patients who progressed after abemaciclib plus endocrine therapy (ET), using a strategy of switching aromatase inhibitor/tamoxifen to fulvestrant (FUL) or switching FUL to AI while continuing abemaciclib. The key finding was that continuing abemaciclib with endocrine therapy switch after progression produced measurable progression-free survival (PFS) outcomes in this post–CDK4/6 inhibitor setting. This is clinically significant because it tests whether abemaciclib can be reused (“rechallenged”) to extend benefit for patients with limited options after prior CDK4/6 inhibitor exposure.

Nishimura M, Kogawa T, Sugiyama K et al. · Breast cancer research and treatment · (2026) · View on PubMed ↗ · Free PDF ↗

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.

The TANGENT phase III randomized study evaluated emactuzumab, a CSF-1R inhibiting monoclonal antibody, for treatment of tenosynovial giant cell tumors (TGCT) in patients who were candidates for systemic therapy. The trial design targets tumor biology driven by CSF-1R signaling by blocking CSF-1R dimerization, aiming to reduce tumor-associated macrophage activity and improve clinical outcomes. If effective, emactuzumab could provide a shorter, less burdensome alternative to long-term CSF-1R pathway inhibitor therapy for TGCT patients who are not suitable for surgery or have high recurrence risk.

Gelderblom H, Palmerini E, van de Sande M et al. · Future oncology (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer.

This review article summarized tailored strategies to overcome third-generation EGFR TKI resistance in EGFR-mutated non-small cell lung cancer, focusing on resistance mechanisms such as on-target EGFR alterations (e.g., EGFR C797S), off-target pathway activation (e.g., MET or HER2 amplification, RAS-MAPK signaling, and oncogenic fusions), and neuroendocrine transformation to small-cell lung cancer. The key finding is that resistance is multifactorial and requires treatment tailoring based on tumor molecular profiling and the specific resistance route. Clinically, it supports algorithmic decision-making that matches next-line therapies to the dominant resistance mechanism after third-generation EGFR inhibition.

Saporita I, Farinea G, Lombardi E et al. · Expert opinion on therapeutic targets · (2026) · View on PubMed ↗

Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.

This review discusses tumor evolution by integrating signaling pathways and molecular mechanisms with therapeutic target opportunities, emphasizing how modern technologies (high-throughput sequencing, single-cell and spatial omics, lineage tracing, computational modeling, and noninvasive biopsy) enable dynamic tracking of heterogeneity. The key finding is that evolutionary dynamics can be characterized and linked to actionable vulnerabilities using these emerging approaches. Scientifically, it supports evolution-informed precision oncology strategies that adapt treatment to changing tumor states.

Zhang KY, Zhu XZ, Yan YX et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

This phase 3 randomized superiority trial (EBMT-SAAWP RACE; NCT02009747) studied whether adding eltrombopag to standard immunosuppressive therapy (horse ATG plus cyclosporine A) improves long-term outcomes in treatment-naive severe aplastic anemia, comparing hATG 40 mg/kg ×4 days plus CsA 5 mg/kg/day (arm A) versus the same regimen plus eltrombopag 150 mg/day (arm B). The final 2-year analysis showed a significantly higher 2-year cumulative incidence of complete response with eltrombopag added (62.4% vs the lower rate in the control arm). Clinically, this provides durable evidence that eltrombopag improves response rates when used as front-line therapy for severe aplastic anemia.

Risitano AM, Iacobelli S, Kulasekararaj A et al. · American journal of hematology · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodegeneration & neuroinflammation biomarkers/mechanisms

Microglial states revisited: from homeostasis to disease.

This review studied how microglial states in the CNS are shaped across development, brain region, sex, age, genotype, and environment, using advances in single-cell/single-nucleus transcriptomics, chromatin accessibility profiling, and spatial multi-omics. It found that microglia do not fit simple binary “resting vs activated” or M1/M2 frameworks, instead occupying a multidimensional transcriptional state space spanning homeostasis and disease. The scientific significance is that it reframes microglial biology for more accurate interpretation of neuroinflammatory mechanisms and therapeutic targeting.

Eggen BJL, Kooistra SM · Nature reviews. Neuroscience · (2026) · View on PubMed ↗

Complement dysregulation during the early phases of synucleinopathy.

This study examined complement dysregulation during early phases of synucleinopathy in a rat α-syn pre-formed fibril (PFF) model (details truncated in the abstract). The key finding is that complement cascade activation occurs in relation to pathological α-syn before overt neurodegeneration, addressing whether complement activation is primary to α-syn pathology rather than secondary to neuronal loss. This is significant because it clarifies immune mechanisms that may drive Parkinson’s disease progression and supports complement as a potential early therapeutic target.

Khan H, Gifford M, Kordbacheh A et al. · Acta neuropathologica · (2026) · View on PubMed ↗ · Free PDF ↗

Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.

Large-scale plasma proteomics was used to profile 1,318 blood samples from international cohorts to find protein biomarkers for differential diagnosis and molecular staging across major neurodegenerative dementias (Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia). More than 200 proteins were dysregulated, with glial fibrillary acidic protein (GFAP) increasing along the Alzheimer’s disease continuum and integrin alpha-V and integrin alpha-M (ITGAV/ITGAM) consistently reduced across disease groups. This provides blood-based, proteome-derived signatures that could enable scalable clinical stratification and monitoring across dementia subtypes.

Bellomo G, Vermunt L, In ‘t Veld S et al. · Nature aging · (2026) · View on PubMed ↗ · Free PDF ↗

Use of blood-based neurofilament light chain as an endpoint in clinical trials of neurodegenerative conditions: a scoping review.

This scoping review examined how blood-based neurofilament light chain (NfL) measured in serum or plasma is used as an endpoint in interventional clinical trials for neurodegenerative conditions published from 2013–2024. The key finding was that blood NfL is increasingly adopted as a neuroaxonal injury biomarker endpoint, with trial designs and analytical approaches varying across studies. This is significant because it helps standardize how blood NfL can be incorporated into future neurodegenerative clinical trials to improve endpoint sensitivity and translational comparability.

Zheng Y, Bhalala OG, Chin KS et al. · Journal of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons.

This preclinical study compared sulforaphane (SF) with omaveloxolone (Omav) and dimethyl fumarate (DMF) in induced pluripotent stem cell (iPSC)-derived sensory neurons from patients with Friedreich ataxia (FRDA) carrying expanded GAA repeats in the FXN gene (including a line with 550 GAA1 repeats). The key finding was that SF has therapeutic activity in these patient-derived neurons, supporting its ability to increase FXN expression and modulate epigenetic, inflammatory, and oxidative stress pathways relative to or alongside approved and comparator agents. This is significant because it strengthens the translational rationale for SF as a potential additional or alternative therapy for FRDA beyond omaveloxolone.

Yang W, Thompson B, Miellet S et al. · Antioxidants & redox signaling · (2026) · View on PubMed ↗

Soluble high-molecular-weight amyloid-β species derived from amyloid-β-laden brains induce cerebral β-amyloidosis.

This study investigated whether soluble high-molecular-weight amyloid-β (Aβ) species (>150 kDa) isolated from amyloid-β-laden brains—using size-exclusion chromatography—from both amyloid precursor protein transgenic mice and Alzheimer’s disease patients can seed pathology in vivo. Intrahippocampal injection of these soluble >150 kDa Aβ species dramatically accelerated cerebral β-amyloidosis in transgenic mice compared with controls. Scientifically, it identifies a specific Aβ “seed” molecular property that can drive in vivo plaque-like spreading, informing mechanisms of Alzheimer’s disease progression and potential seed-targeting strategies.

Kashiwagi-Hakozaki M, Uchigami H, Naka Y et al. · Brain communications · (2026) · View on PubMed ↗ · Free PDF ↗

Distribution of Big Tau Isoforms in the Human Central and Peripheral Nervous System.

This study characterized the distribution and disease relevance of “big tau” (tau isoforms containing exon 4a) across the human central and peripheral nervous system using mass spectrometry sequencing and mapping. It found that big tau isoforms are anatomically distributed across CNS and PNS regions and that their composition differs in postmortem tissues from Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and controls. The work is significant because it provides a mass-spectrometry-based atlas of big tau that may refine biomarker and mechanistic studies of tau pathology beyond canonical “small” tau.

Koppisetti RK, Barthélemy NR, Horie K et al. · Annals of neurology · (2026) · View on PubMed ↗ · Free PDF ↗

Blood-based multimodal biomarker models for differentiating early-onset Alzheimer’s disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study.

This longitudinal LEAF study assessed blood-based multimodal biomarker models to differentiate early-onset Alzheimer’s disease (EOAD) from early-onset frontotemporal dementia (EOFTD) in 185 participants (EOAD n=150, EOFTD n=35, age ≤65) by measuring plasma p-tau217, p-tau181, neurofilament light (NfL), and GFAP via immunoassays. Plasma p-tau217 and p-tau181 showed high diagnostic discrimination (AUC 0.831 and 0.862, respectively) for distinguishing EOAD from EOFTD. These results support the clinical utility of plasma phospho-tau biomarkers, alone or in multimodal panels, for earlier and more accurate diagnosis in early-onset dementia populations.

Kwon HS, Moon SY, Hwang M et al. · Journal of neurology · (2026) · View on PubMed ↗

---

Infectious disease virology & host-pathogen interactions

Circulating alpha-1 antitrypsin and its c-terminal peptides differentiate bacterial from viral community-acquired pneumonia.

Researchers studied whether circulating alpha-1 antitrypsin (AAT) and nine AAT-derived C-terminal peptides can distinguish bacterial from viral community-acquired pneumonia in 81 prospectively enrolled adults at hospital admission (day 0) and day 3. Using ELISA for AAT and LC-based quantification for the peptides, they found that AAT/peptide profiles can differentiate bacterial versus viral CAP. This is significant because it could reduce inappropriate antimicrobial use by providing a host-protein/peptide diagnostic signal early in infection.

Pashai Fakhri M, Börner FR, Held J et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Viral syncytia evolve to resist interferon.

Researchers studied how SARS-CoV-2 (and Spike-replacement vesicular stomatitis virus) syncytia formation affects antiviral interferon responses in cultured cells, human lung cell cultures, and hACE2 transgenic mice. They found that Spike (S)-mediated syncytia impair interferon antiviral effects and that Delta- and Omicron S substitutions that modulate syncytia formation similarly modulate interferon resistance, also reducing antibody-mediated neutralization. This is clinically significant because it links a viral cell-fusion phenotype to immune evasion, informing how variants may alter disease severity and treatment responses.

Li T, Kang I, Ye J et al. · Nature communications · (2026) · View on PubMed ↗ · Free PDF ↗

Mapping in-cell protein contact sites reveals hijacking of paraspeckles during influenza A virus infection.

In human cells infected with influenza A virus (IAV), the authors mapped native protein–protein contact sites using in-cell cross-linking mass spectrometry combined with structural modeling and functional assays. They uncovered previously unrecognized virus–host interactions, including host factors in the membrane-bound endoplasmic reticulum–Golgi system that regulate maturation of distinct haemagglutinin glycoforms, and evidence of paraspeckle hijacking during infection. These results clarify how IAV exploits spatially organized host processes and identify specific host pathways that may be targeted to limit viral replication.

Kotova I, Mühlberg L, Gilep K et al. · Nature microbiology · (2026) · View on PubMed ↗ · Free PDF ↗

All-trans retinoic acid suppresses systemic inflammation induced by severe fever with thrombocytopenia syndrome virus in mice.

The study examined all-trans retinoic acid (ATRA) in severe fever with thrombocytopenia syndrome virus (SFTSV) infection by correlating patient serum vitamin A/ATRA depletion with disease severity and then testing ATRA in an SFTSV mouse model. ATRA administration suppressed virus-induced systemic hyperinflammation via peroxisome proliferator-activated receptor-γ (PPARγ), which downregulated macrophage activator protein-1 (AP-1) transcriptional activity. This supports a mechanistic, host-directed anti-inflammatory strategy for SFTSV that could reduce mortality risk by modulating innate immune signaling.

Yu X, Wu J, Yin X et al. · Nature microbiology · (2026) · View on PubMed ↗

Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis.

This systematic review and meta-analysis compared high-dose versus standard-dose inactivated influenza vaccines (HD-IIV 60 μg haemagglutinin per strain vs SD-IIV) in adults aged 65 years or older using randomized controlled trial evidence. It found that HD-IIV had different effects on hospitalization outcomes and mortality compared with SD-IIV, clarifying comparative efficacy and safety in older adults. The results are clinically important for informing influenza vaccination policy and product choice in geriatric populations at high risk of severe outcomes.

Zhao W, Lian R, Zhao Y et al. · The lancet. Healthy longevity · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy.

This preclinical study developed viral protease-initiated lytic cell death (VID), a universal mRNA therapeutic platform that engineers gasdermin-D (GSDMD) with viral protease-specific cleavage motifs to trigger lytic cell death in virus-infected cells. Using hepatitis A virus (HAV) as a model, lipid nanoparticle (LNP)-encapsulated VIDA mRNA abolished viral replication and shedding in vivo and reduced liver injury. The work is significant as a potential broadly applicable antiviral mRNA strategy that converts viral protease activity into targeted, immune-relevant cell killing.

Li L, Yan XL, Wang HY et al. · Cell · (2026) · View on PubMed ↗

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.

This randomized clinical trial evaluated clesrovimab, a long-acting monoclonal antibody, in infants at increased risk for severe respiratory syncytial virus (RSV) disease across two RSV seasons, comparing clesrovimab (105 mg) with palivizumab in season 1 and assessing safety of a higher clesrovimab dose (210 mg) in season 2. The key finding was that clesrovimab was safe and tolerable in this high-risk infant population across the second RSV season. Clinically, it extends evidence for sustained RSV prophylaxis with clesrovimab beyond the first season for infants who remain at risk.

Zar HJ, Bont LJ, Manzoni P et al. · JAMA pediatrics · (2026) · View on PubMed ↗ · Free PDF ↗

Divergent Autophagy Pathways in Plasmodium: Mechanisms, Functions, and Therapeutic Potential.

This review studied autophagy mechanisms in the malaria parasite Plasmodium, focusing on the reduced but functional set of autophagy-related (ATG) proteins and the ubiquitin-like marker/effector ATG8. It found that Plasmodial autophagy shows divergent, branched localization patterns with ATG8 associated with the apicoplast membrane, implying parasite-specific roles beyond canonical autophagy. These findings support targeting Plasmodium ATG8/branching autophagy pathways as potential therapeutic vulnerabilities against malaria.

Rajput S, Mehra P, Nandi R et al. · Molecular microbiology · (2026) · View on PubMed ↗

---

Immunology & inflammation (non-cancer)

Endothelial cell-intrinsic NOD2 signaling regulates the intestinal immune response through the generation of effector and memory T cells.

The authors investigated how endothelial cell-intrinsic NOD2 signaling shapes intestinal immunity by studying NOD2 engagement by muramyl dipeptide and its downstream effects on T cell generation and memory formation. They found that NOD2 signaling in endothelial cells regulates the intestinal immune response through generation of effector and memory T cells, linking innate sensing to adaptive T cell homeostasis. This provides a mechanistic explanation for how NOD2 variants (major Crohn’s disease risk) can paradoxically associate with impaired homeostasis despite NOD2 ligand being immunostimulatory.

Tsankov BK, Denney M, Ahn JSY et al. · Nature immunology · (2026) · View on PubMed ↗ · Free PDF ↗

NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer.

This work studied the role of nucleotide-binding oligomerization domain-containing proteins NOD1 and NOD2 in macrophages in adaptive immune resistance to cancer therapies. In murine tumor models, genetic ablation of NOD1/2 or RIPK2 and pharmacologic inhibition of the pathway reduced resistance across multiple antitumor modalities, including immune checkpoint blockade, adoptive T-cell therapy, and cytotoxic chemotherapy. These findings identify NOD1/2–RIPK2 signaling in macrophages as a potential therapeutic target to overcome resistance to diverse cancer treatments.

Wei X, Yang L, Wang Y et al. · Signal transduction and targeted therapy · (2026) · View on PubMed ↗ · Free PDF ↗

Multiomics integrative bioinformatics analysis of gene expression characteristics and molecular mechanisms in preeclampsia placental tissue.

This multiomics integrative bioinformatics study analyzed preeclampsia placental tissue by integrating multiple placental transcriptome and single-cell sequencing datasets from GEO using differential expression, WGCNA, and machine learning to define molecular subtypes and mechanisms. The key output was identification of gene expression characteristics and co-expression modules associated with preeclampsia, supporting placental dysfunction as a central pathogenic driver. These computational findings can generate candidate biomarkers and therapeutic targets for improving mechanistic understanding and stratification of preeclampsia.

Li N, Tian L, Wei H · Artificial cells, nanomedicine, and biotechnology · (2026) · View on PubMed ↗ · Free PDF ↗

Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis.

This systematic literature review assessed reported associations between viral infections and antiviral vaccinations and the development of autoimmune encephalitis subtypes, including anti-NMDAR autoimmune encephalitis. The key finding was that specific viral infection and vaccination links are described across AIE subtypes, but the review highlights that a subtype-specific, frequency-aware synthesis has been lacking and is needed. Clinically, clarifying these immunological triggers can improve risk counseling and diagnostic suspicion when patients present with new-onset autoimmune encephalitis after infections or vaccination.

Bamberg S, Schulte-Frankenfeld PM, Kreye J · Brain, behavior, & immunity - health · (2026) · View on PubMed ↗ · Free PDF ↗

γδ T cells show distinct responses to CMV after stem cell transplantation.

This study examined how γδ T cells respond to cytomegalovirus (CMV) after allogeneic hematopoietic stem cell transplantation (aHSCT) by tracking clones over time. Using longitudinal single-cell RNA sequencing combined with paired T cell receptor sequencing across five post-transplant time points, it found patient-specific expansion of non-Vγ9Vδ2 γδ T cell clones, particularly within Vδ1+ and Vδ3+ subsets, associated with differences in CMV reactivation status. The findings are significant because they define clonal and functional dynamics of γδ T cell immunity to CMV, informing immune monitoring and potential strategies to manage CMV after aHSCT.

Sibbertsen F, Song Z, Ly C et al. · Journal of molecular medicine (Berlin, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Gut microbiota-driven metabolites modulate the development of stress-related mental disorders.

This review synthesizes evidence from preclinical and clinical studies on how gut microbiota–derived metabolites influence the development of stress-related mental disorders (e.g., depression, anxiety, PTSD). The key finding is that microbiota-driven metabolite changes can enter systemic circulation and modulate host physiology in ways that affect stress biology and disorder progression. This supports metabolite-centered mechanisms as potential targets for future therapeutic strategies and biomarker development in stress-related psychiatric disease.

Yuan M, Qin F, Wu L et al. · Translational psychiatry · (2026) · View on PubMed ↗ · Free PDF ↗

Lyophilized platelet derived extracellular vesicles promote hemostasis and attenuate intracranial hemorrhage following traumatic brain injury.

This study evaluated whether lyophilized platelet-derived extracellular vesicles (LPEVs) promote hemostasis and reduce intracranial hemorrhage (ICH) after traumatic brain injury (TBI) using characterization by flow cytometry, scanning electron microscopy, and Nanosight, plus in vitro testing on human brain endothelial cell monolayers and a murine TBI model. LPEV treatment improved hemostatic function, preserved blood-brain barrier integrity, and attenuated ICH in the TBI setting. The results support LPEVs as a potential cell-free biologic therapy to reduce fatal bleeding complications after TBI.

Trivedi A, Miyazawa B, Fields AT et al. · Journal of translational medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Efficacy of magnesium-calcium ionic oral rinse for primary burning mouth syndrome: a randomized, double-blind, placebo-controlled trial.

This randomized, double-blind, placebo-controlled trial studied the efficacy and safety of a magnesium-calcium ionic oral rinse in patients with primary burning mouth syndrome (BMS). The key finding was that the magnesium-calcium oral rinse improved outcomes compared with placebo (with safety assessed as part of the trial). Clinically, this supports a local, ionic microenvironment–modulating approach as a potential treatment to reduce chronic orofacial burning symptoms while avoiding systemic adverse effects.

Carrió N, Garawani BE, Alahmad A et al. · BMC oral health · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cardiovascular disease & cardiometabolic mechanisms

Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction.

This article reviewed and analyzed experience from positive and neutral heart failure with preserved ejection fraction (HFpEF) trials to assess whether phenotypic heterogeneity characterization yields mechanistic insight or predicts treatment response in patients with HFpEF. The key finding was that subgroup analyses based on phenotypic diversity have not reliably identified responders or translated into broadly effective, mechanism-driven therapies. Scientifically, it argues that current approaches to phenotyping HFpEF may be insufficient and highlights the need for better causal stratification strategies.

Packer M, Schiattarella GG, Petrie MC et al. · Circulation · (2026) · View on PubMed ↗ · Free PDF ↗

Loss of ATP-Dependent Citrate Lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling.

This study investigated the role of ATP-dependent citrate lyase (ACLY/Acly) in human heart tissue from healthy donors and patients with nonischemic cardiomyopathy and used CRISPR-based approaches to model ACLY loss. The key finding was that loss of ATP-dependent citrate lyase caused left ventricular dysfunction through metabolic remodeling, consistent with impaired acetyl-CoA production and downstream lipid synthesis programs. Clinically, it identifies ACLY-dependent metabolic adaptation as a driver of cardiomyopathy progression and a potential therapeutic target.

Liu S, Gammon ST, Tan L et al. · Circulation · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Small Extracellular Vesicles From Cardiomyocytes Activate Microglia Aggravating HFpEF.

Researchers studied whether small extracellular vesicles (sEVs) released from cardiomyocytes activate hypothalamic microglia and worsen HFpEF using a mouse model combining a long-term high-fat diet with the nitric oxide synthase inhibitor L-NAME. In this model, microglial activation and hypothalamic inflammation were observed, and microglial depletion with PLX3397 suppressed sympathetic activation, implicating cardiomyocyte-derived sEVs in HFpEF neuroinflammation. These mechanistic findings suggest that targeting the heart-to-brain sEV–microglia axis could be a therapeutic strategy for HFpEF.

Men L, Wang Q, Ren B et al. · Circulation research · (2026) · View on PubMed ↗

Activity-based proteomics analysis revealed that DNJ directly targeted ATP5F1 to alleviate high glucose induced cardiomyocyte injury.

This study examined the cardioprotective mechanism of the natural alkaloid 1-deoxynojirimycin (DNJ) in cardiomyocytes exposed to high glucose, using activity-based protein profiling (ABPP) to identify direct DNJ targets and mechanistic assays to define downstream effects. DNJ directly targeted ATP5F1 (an ATP synthase subunit) and this interaction alleviated high-glucose-induced cardiomyocyte injury. Scientifically, the work links DNJ to a specific mitochondrial protein target (ATP5F1), providing a mechanistic basis for developing DNJ or related strategies for diabetic cardiomyopathy.

Li X, Chen Y, Yang H et al. · Cell communication and signaling : CCS · (2026) · View on PubMed ↗ · Free PDF ↗

---

Pulmonary/respiratory medicine & critical care

Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.

The LUNA programme design describes four phase III, multicentre, randomized, double-blind, parallel-group, placebo-controlled studies testing tozorakimab (anti-IL-33 monoclonal antibody) in symptomatic COPD patients with a history of exacerbations despite optimized inhaled therapy. The trials target both IL-33 reduced (IL-33red) and oxidised (IL-33ox) activity and are designed to evaluate efficacy and safety across the programme’s studies (including OBERON and TITANIA). This provides the framework for determining whether IL-33 blockade can reduce exacerbations and improve outcomes in high-risk COPD populations.

Watz H, Sciurba FC, Bonini M et al. · BMJ open respiratory research · (2026) · View on PubMed ↗ · Free PDF ↗

Prone positioning in ARDS.

This article reviewed the evidence and clinical role of prone positioning in acute respiratory distress syndrome (ARDS), including early use in intubated patients with PaO2/FIO2 <150 mmHg and the awake prone position (APP) approach used during and beyond the COVID-19 era. The key finding was that prone positioning consistently improves oxygenation in both intubated and non-intubated ARDS populations, with APP requiring further confirmation in non-COVID settings and routine ICU practice. Clinically, it supports prone positioning as an integral lung-protective ventilation strategy while highlighting where additional evidence is needed to guide broader implementation.

Ehrmann S, Li J, Liu L et al. · Intensive care medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Caffeine and Cardiovascular Disease: A Scientific Statement From the American Heart Association.

This American Heart Association scientific statement synthesized evidence on caffeine intake and cardiovascular disease outcomes and risk factors across human observational studies and differing patterns of acute versus chronic consumption. Overall findings suggest complex, heterogeneous relationships that often show an inverse J-shaped association for naturally occurring caffeinated beverages, with effects varying by individual propensity and caffeine source. Clinically, the statement supports nuanced guidance on caffeine consumption rather than a one-size-fits-all recommendation for cardiovascular risk.

Marcus GM, Hu FB, van Dam RM et al. · Circulation · (2026) · View on PubMed ↗

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

This study profiled the airway transcriptome in severe asthma by comparing bronchial biopsy/brush samples from UK Refractory Asthma Stratification Programme participants with type 2 (T2) biomarker-high, -intermediate, and -low phenotypes, plus healthy controls, before and after high-dose inhaled corticosteroids (ICS). The key finding was identification of distinct dysregulated genes and molecular pathways associated with T2 biomarker status, including differences in pathways when T2 cytokine activity is suppressed. Scientifically, these airway transcriptomic signatures could help explain heterogeneity in steroid response and guide biomarker-driven stratification of severe asthma.

Shen J, Chaudhuri R, Bicknell S et al. · Allergy · (2026) · View on PubMed ↗ · Free PDF ↗

Cigarette Smoke-Exposed Alveolar Epithelial Cell-Derived Exosomes Exacerbate Skeletal Muscle Dysfunction Through HDAC2 Signalling.

This mechanistic study examined how cigarette smoke–exposed alveolar epithelial cell–derived exosomes affect skeletal muscle dysfunction in the context of COPD, with emphasis on histone deacetylase 2 (HDAC2) signaling. It found that blocking exosome signaling with the exosome inhibitor GW4869 mitigated cigarette smoke–induced skeletal muscle injury and implicated HDAC2-dependent pathways in the exosome-driven exacerbation of muscle dysfunction. Scientifically, it identifies an exosome–HDAC2 axis as a plausible mediator of COPD-related sarcopenia and a potential therapeutic target.

Li C, Ou M, Jiang G et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

Hemoperfusion during extracorporeal membrane oxygenation: an updated systematic review and meta-analysis of 8,151 patients.

This systematic review and meta-analysis evaluated adults receiving extracorporeal membrane oxygenation (ECMO) with hemoperfusion (ECMO+HP) versus ECMO alone, using data from 8,151 patients across included studies. The key finding is an updated assessment of hemoperfusion’s efficacy and safety in ECMO populations, with analyses stratified by study design (RCT vs non-RCT), ECMO type (VA vs VV), and etiology (cardiogenic shock vs cardiac arrest). Clinically, it informs whether adding hemoperfusion improves outcomes such as all-cause mortality and helps guide practice in critically ill ECMO patients.

Xie T, Yang C, Tao H et al. · Critical care (London, England) · (2026) · View on PubMed ↗ · Free PDF ↗

Sodium bicarbonate therapy in severe metabolic acidemia: an individual patient data meta-analysis of the BICAR-ICU and BICAR-ICU2 trials.

This individual patient data meta-analysis pooled the BICAR-ICU and BICAR-ICU2 randomized trials to assess intravenous sodium bicarbonate therapy in adults with severe metabolic acidemia (pH ≤ 7.20), comparing bicarbonate titrated to pH ≥ 7.30 versus no bicarbonate. The key finding is an evaluation of effects on 90-day mortality and renal replacement therapy (RRT) use, including exploration of heterogeneity across prespecified subgroups. Scientifically and clinically, it clarifies which patient groups may benefit from bicarbonate in severe acidemia and refines decision-making in critical care.

Fosset M, Pensier J, Jabaudon M et al. · Critical care (London, England) · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

---

Autoimmune & inflammatory disease therapeutics

Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis.

This post-hoc analysis evaluated tezepelumab 210 mg versus placebo every 4 weeks in Japanese adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), stratified by eosinophilic chronic rhinosinusitis defined by the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (ECRS) endotype. Tezepelumab improved nasal polyp outcomes (including total nasal polyp score) and sinonasal symptoms and reduced the need for surgery and systemic corticosteroids across eosinophilic subgroups. The findings support tezepelumab as an endotype-informed biologic option for CRSwNP management in Japanese patients.

Fujieda S, Otori N, Han JK et al. · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · (2026) · View on PubMed ↗ · Free PDF ↗

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

The POETYK PsA-2 phase 3 randomized, double-blind trial evaluated the efficacy and safety of deucravacitinib, an oral selective TYK2 inhibitor, in patients with active psoriatic arthritis (PsA) who were biologic-naïve or previously treated with tumor necrosis factor inhibitors. Over 52 weeks, patients received deucravacitinib 6 mg daily versus placebo and an apremilast 30 mg twice-daily safety reference arm, with the primary endpoint based on ACR20 improvement (reported through the abstract). If confirmed in full results, deucravacitinib could expand targeted oral options for PsA with a mechanism distinct from TNF inhibitors and PDE4 inhibition.

Mease PJ, Chandran V, Armstrong AW et al. · Arthritis & rheumatology (Hoboken, N.J.) · (2026) · View on PubMed ↗

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial.

This randomized trial studied ruxolitinib cream in adults (≥18 years) with moderate atopic dermatitis (IGA 3, EASI >7, itch NRS ≥4) who had inadequate response/intolerance/contraindication to topical corticosteroids and topical calcineurin inhibitors in the prior 12 months (TRuE-AD4, NCT06238817). The 8-week results reported improved disease and itch outcomes with ruxolitinib cream compared with the trial’s control regimen (details truncated in the abstract). These findings support ruxolitinib cream as a potential topical escalation option for steroid/TCI-refractory moderate atopic dermatitis, potentially reducing the need for systemic therapy.

Carrascosa JM, Prajapati VH, Hong HC et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · (2026) · View on PubMed ↗ · Free PDF ↗

Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study.

This retrospective real-world comparative study evaluated telitacicept versus conventional immunotherapy in patients with AChR-antibody-positive generalized myasthenia gravis (AChR-Ab+ gMG), including 215 total patients with propensity score matching (35 per group). The key finding was that telitacicept showed differences in treatment response and safety outcomes relative to conventional immunotherapy in this broader AChR-Ab+ population than typical RCT cohorts (response metrics truncated in the abstract). Clinically, the study supports telitacicept’s effectiveness and safety considerations for real-world management of AChR-Ab+ gMG.

Yang Y, Kang N, Zhu Y et al. · ImmunoTargets and therapy · (2026) · View on PubMed ↗ · Free PDF ↗

---

Musculoskeletal & tissue repair (including OA/sarcopenia)

Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis.

This preclinical study developed a mitochondria-targeted MXene-based nanozyme (MS@PMXene-TK) incorporating a mitochondria-targeting peptide (MTP-131), a ROS-responsive thioketal-linked PEG-TK shell, and a chondro-inductive peptide (SPPEPS) to treat osteoarthritis models. The nanozyme promoted mitophagy and inhibited mtDNA-triggered cGAS/STING inflammatory signaling, thereby addressing mitochondrial dysfunction and chronic inflammation in osteoarthritis. These results suggest a subcellularly targeted therapeutic platform that could modulate the cGAS/STING pathway and improve cartilage repair in OA.

Li T, Zheng A, Zhu C et al. · Bioactive materials · (2026) · View on PubMed ↗ · Free PDF ↗

Electroacupuncture Treatment on Sarcopenia in Patients Undergoing Maintenance Haemodialysis: An Effective Therapy.

This randomized controlled clinical trial studied electroacupuncture (EA) for sarcopenia in 36 maintenance haemodialysis (MHD) patients, comparing an EA group receiving 24 sessions (30 minutes, three times weekly) versus a control group continuing usual care. It found that EA improved sarcopenia outcomes compared with control over the intervention period. The clinical significance is that EA may be an effective adjunct therapy to improve muscle health in patients with sarcopenia undergoing long-term haemodialysis.

Chen R, Qian Q, Wang B et al. · Journal of cachexia, sarcopenia and muscle · (2026) · View on PubMed ↗ · Free PDF ↗

---

Endocrinology, diabetes & metabolic health

Effects of Lifestyle Modification on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis evaluated whether lifestyle modification interventions reduce intrapancreatic fat deposition (IPFD) in humans by synthesizing PubMed and Embase studies. The key finding was that lifestyle modification shows measurable effects on IPFD, supporting IPFD as a modifiable ectopic fat depot linked to metabolic and pancreatic disease risk. Scientifically, this strengthens the rationale for lifestyle-based strategies to target pancreatic fat accumulation, potentially informing prevention and risk-reduction approaches for endocrine and exocrine pancreatic disorders.

Ahmad S, Sul HH, Danpanichkul P et al. · Current obesity reports · (2026) · View on PubMed ↗ · Free PDF ↗

Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial.

This multicenter randomized placebo-controlled trial (FAMILIAR) evaluated imeglimin as an add-on to DPP-4 inhibitors in Japanese adults with type 2 diabetes inadequately controlled on DPP-4 monotherapy, with a 24-week double-blind phase followed by an 80-week open-label extension (104 weeks total). The key finding was that imeglimin provided sustained glycemic efficacy through week 104 with an acceptable safety profile, including in elderly patients (primary endpoint HbA1c change at week 104; detailed results truncated). This supports long-term use of imeglimin plus DPP-4 inhibitors for durable glycemic control in Japanese patients with type 2 diabetes.

Shimoda M, Osonoi T, Iwamoto M et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗

Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulation.

This preclinical study investigated the Akkermansia muciniphila–derived hexapeptide LKLKLL and its effects on glucolipid metabolism via GLP-1/GIP dual modulation in cell models and mouse models of metabolic disease. It found that LKLKLL reduced body weight in high-fat diet–induced obese mice, improved glucose tolerance in diabetic models, and enhanced GLP-1 secretion (with dual GLP-1/GIP modulation reported). These results support LKLKLL as a defined, translational alternative to live A. muciniphila for obesity and diabetes interventions.

Li Y, Ye D, Fu C et al. · Gut microbes · (2026) · View on PubMed ↗ · Free PDF ↗

Work-to-sleep ratio as a novel marker of NAFLD risk: evidence from U.S. and Korean national cohorts.

This cohort study evaluated whether the work-to-sleep ratio (WSR) predicts nonalcoholic fatty liver disease risk (MASLD/NAFLD) using U.S. and Korean national cohorts. The key finding is that WSR serves as a novel behavioral marker of NAFLD risk beyond work hours or sleep duration alone by capturing the balance between occupational demand and sleep recovery. Clinically, it suggests a practical, modifiable risk metric for identifying individuals at higher risk for MASLD.

Zhong Y, Kou Y, Lu Z et al. · Nutrition & metabolism · (2026) · View on PubMed ↗ · Free PDF ↗

---

Aging, frailty, sleep & longevity interventions

Genome-wide association analyses of borderline personality disorder identify 11 loci and highlight shared risk with mental and somatic disorders.

A genome-wide association study meta-analysis of borderline personality disorder (BPD) was conducted in European-ancestry samples (12,339 cases/1,041,717 controls discovery; 685 cases/107,750 controls replication) to identify susceptibility loci and risk genes. The study identified 11 independent associated genomic loci, 9 risk genes, estimated SNP-heritability of 17.3%, and produced polygenic scores (PGS) explaining 4.6% of BPD liability-scale variance. These findings refine the genetic architecture of BPD and support shared genetic risk with other mental and somatic disorders, improving targets for future mechanistic work and risk prediction.

Streit F, Awasthi S, Hall ASM et al. · Nature genetics · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Multidomain Lifestyle Intervention in Mild Cognitive Impairment: Subgroup Analysis of the SUPERBRAIN-MEET Randomized Trial.

This prespecified subgroup analysis of the 24-week SUPERBRAIN-MEET randomized controlled trial studied whether a multidomain lifestyle intervention (MLI) delivered via face-to-face sessions plus digital platforms improved cognition differently by sociodemographic factors, digital readiness, baseline cognitive status, and vascular risk profiles in adults with mild cognitive impairment (MCI). The key finding was that the cognitive benefits of the MLI varied across these baseline subgroups, indicating differential responsiveness rather than a uniform effect. These results support tailoring multidomain lifestyle programs for MCI by accounting for patient digital readiness, baseline cognition, and vascular risk to maximize dementia-prevention impact.

Kim DA, Lee SM, Sun K et al. · Neurology · (2026) · View on PubMed ↗

Accelerated Epigenetic and Inflammatory Aging and Intrinsic Capacity.

This population-based cohort study examined cross-sectional and longitudinal associations between accelerated epigenetic and inflammatory aging and intrinsic capacity (IC), including domain-specific IC and sex differences, in older adults. The key finding was that accelerated epigenetic and inflammatory aging was associated with lower intrinsic capacity and that these aging measures related to IC decline over time. Scientifically, it links molecular aging signatures to functional capacity, supporting preventive, function-oriented strategies for healthy longevity.

Rouch L, De Souto Barreto P, Rolland Y et al. · JAMA network open · (2026) · View on PubMed ↗ · Free PDF ↗

Gut Metabolism Links Precision Nutrition, Exercise, and Healthspan in Drosophila melanogaster.

This study in Drosophila melanogaster tested whether a precision-nutrition and exercise multimodal intervention—methionine restriction (MR), taurine supplementation (Tau), and moderate exercise—extends healthspan and lifespan under a chemically defined diet. The combination additively increased lifespan while preserving reproductive capacity and improving locomotor function, and targeted metabolomics with stable isotope tracing indicated increased mitochondrial TCA cycle flux and improved gut redox homeostasis. Scientifically, it links gut metabolism to coordinated systemic benefits, supporting metabolite-centered approaches to designing longevity interventions.

Wei F, Liu S, Sun Y et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Frailty mediates the association between sleep duration and physical, psychological, and cognitive multimorbidity in Chinese middle-aged and older adults.

This study used data from the China Health and Retirement Longitudinal Study (CHARLS) to test whether frailty mediates the association between sleep duration and physical, psychological, and cognitive multimorbidity (PPC-MM) in Chinese middle-aged and older adults. Using multivariate logistic regression and Cox proportional hazards models (with nonlinear dose-response assessed by restricted cubic splines), it found that frailty partially mediated the relationship between sleep duration and PPC-MM risk. These results are important for identifying frailty as a potential intervention target to reduce multimorbidity linked to abnormal sleep duration.

Ding H, Li L, Luo G et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Clinical trial methods, guidelines & health services research

EndoBridge 2025: pearls and highlights.

EndoBridge 2025 was studied as a scientific meeting (October 23–26, 2025) to summarize current advances across endocrinology and metabolism for clinicians and researchers. The key finding is that the congress delivered state-of-the-art lectures and case-based discussions covering pituitary, thyroid, adrenal, bone metabolism, neuroendocrine tumors, diabetes, obesity, clinical nutrition, and lipid disorders. Scientifically and clinically, it serves as a curated update platform to translate emerging evidence into practice across major endocrine subspecialties.

Yildiz BO, Armenti M, Brandi ML et al. · Hormones (Athens, Greece) · (2026) · View on PubMed ↗

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

The PACE-B phase 3 randomized trial assessed patient-reported outcomes over 5 years in men with localized prostate cancer assigned to stereotactic body radiotherapy (SBRT) versus conventionally fractionated radiotherapy (CRT). At 5 years, urinary incontinence outcomes were favorable and comparable between SBRT and CRT, with leak-free rates reported as 64% (164/…). These PROM results help contextualize long-term patient experience when choosing between SBRT and CRT, complementing oncologic endpoints.

Cooper S, Patel J, Moore C et al. · European urology · (2026) · View on PubMed ↗ · Free PDF ↗

The 2026 British Society for Rheumatology guideline for pain management in people with inflammatory arthritis.

The 2026 British Society for Rheumatology guideline was developed to address pain management in people with inflammatory arthritis (IA), focusing on evidence gaps in current practice. It synthesizes evidence indicating that long-term opioids and gabapentinoids are often used without trial evidence for efficacy, while non-pharmacological approaches with supportive trial evidence are underused, and it provides a life-course, UK-specific, evidence-based recommendation set. Clinically, this guideline aims to improve pain outcomes and reduce reliance on unsupported pharmacologic strategies in IA care.

Scott IC, Smith TM, Babatunde O et al. · Rheumatology (Oxford, England) · (2026) · View on PubMed ↗ · Free PDF ↗

COVID-19 and Global Perinatal Health: Lessons Learned on Maternal-Neonatal Outcomes, Infant Feeding Practices, and Health Care Economics across Income Settings.

This narrative review synthesized evidence on how the COVID-19 pandemic affected maternal-neonatal outcomes, infant feeding practices, and health care economics across high-income countries and low- and middle-income countries. It found that SARS-CoV-2 infection and health-system disruption together worsened perinatal outcomes and altered neonatal care and breastfeeding, with substantial financial burden on institutions that differed by income setting. These cross-setting lessons are clinically important for designing resilient maternal-newborn services and breastfeeding support during ongoing or future respiratory pandemics.

Gunasekaran V, Woo S, Shetty AK et al. · American journal of perinatology · (2026) · View on PubMed ↗

Global, regional, and national burden of road injuries 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

This Global Burden of Disease Study 2023 analysis estimated the global, regional, and national incidence, mortality, and morbidity of road injuries for 204 countries and territories from 1990 to 2023. It identified changing trends over time and quantified the burden by road injury type and nature-of-injury categories to highlight where intervention gaps remain. These estimates are significant for tracking progress toward road-safety targets and prioritizing evidence-based prevention and trauma-care strategies.

The Lancet. Public health · (2026) · View on PubMed ↗ · Free PDF ↗

Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy.

This study assessed the population health impact of the 2026 American Heart Association/American College of Cardiology/multisociety dyslipidemia guideline on primary prevention statin eligibility and ASCVD risk estimation in nonpregnant adults aged 30–79 years without known ASCVD using NHANES 2017–2023 data. The key finding was that the guideline’s updated risk estimation and statin-eligibility criteria would change the proportion of adults recommended for primary prevention statin therapy at the population level. These results are clinically significant because they quantify how guideline revisions could expand or reclassify statin use and thereby influence future cardiovascular event prevention in the general US adult population.

Anderson TS, Wilson LM, Sussman JB · JAMA · (2026) · View on PubMed ↗ · Free PDF ↗

GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.

This target trial emulation study used Veterans Health Administration data to assess whether GLP-1 receptor agonists (semaglutide or tirzepatide) affect all-cause overdose risk in Veterans with type 2 diabetes and opioid use disorder (OUD) compared with other diabetes medications. The key finding was that GLP-1RA initiation was associated with a change in overdose risk relative to comparator diabetes treatments in this real-world population. This is clinically significant because it provides evidence relevant to repurposing GLP-1RAs for OUD-related overdose risk reduction in a high-risk group.

Kennedy KP, Bremseth-Vining R, Lynch KG et al. · The Journal of clinical psychiatry · (2026) · View on PubMed ↗

Medical Students’ Attitudes, Perceptions, and Self-Reported Familiarity With Artificial Intelligence in Healthcare: A Systematic Review and Meta-Analysis.

A systematic review and meta-analysis synthesized survey-based evidence on medical students’ attitudes, perceptions, and self-reported familiarity with artificial intelligence in healthcare. The analysis focused on harmonization of constructs and heterogeneity across settings, rather than only pooling central estimates, to characterize variation in AI-related responses. The results are significant for designing AI curricula and assessing readiness among future clinicians and educators.

Zhang W, Han J, Han X et al. · JMIR medical education · (2026) · View on PubMed ↗ · Free PDF ↗

PROSPECT guideline for total hip arthroplasty: updated systematic review and procedure-specific postoperative pain management recommendations.

The PROSPECT guideline update performed an updated systematic review to generate procedure-specific postoperative pain management recommendations for elective primary total hip arthroplasty, incorporating new evidence from 2020 to June 2024. The key finding is that the recommendations were revised to reflect emerging data, particularly on motor-sparing regional techniques, while maintaining an evidence-based balance of analgesic efficacy and safety. Clinically, the guideline aims to standardize peri-operative pain control strategies to improve functional recovery after total hip arthroplasty.

Carella M, Bugada D, Van de Velde M et al. · Anaesthesia · (2026) · View on PubMed ↗ · Free PDF ↗

Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review.

This systematic review examined how progression-free survival outcomes for identical myeloma regimens vary across newly diagnosed myeloma trials, focusing on bortezomib/lenalidomide/dexamethasone (VRd) and lenalidomide/dexamethasone (Rd) without transplant. The key finding was that temporal variability in PFS exists across trials using the same regimens, and the review aims to identify factors contributing to this variation, including informative censoring and diagnostic reclassification changes affecting smoldering myeloma inclusion. Scientifically and clinically, it cautions against naive cross-trial comparisons and highlights methodological factors that can bias apparent regimen efficacy over time.

Mohyuddin GR, Vaquera-Alfaro HA, Godara A et al. · EClinicalMedicine · (2026) · View on PubMed ↗ · Free PDF ↗

Evaluating the pharmacokinetics, efficacy and safety of low-dose cannabidiol.

This article reviewed pharmacokinetics, pharmacodynamics, and safety evidence for low-dose cannabidiol (CBD) in humans, focusing on doses ≤2.5 mg/kg or ≤175 mg/day (and PK studies ≤150 mg). It found that low-dose oral CBD produced peak concentration (Cmax) and exposure (AUC) levels 5- to 100-fold lower than those seen with a typical 20 mg/kg dose of Epidiolex, with very limited evidence of physical or neurological effects in healthy volunteers. The significance is that it contextualizes the likely limited systemic exposure and effect size of commonly used low-dose non-prescription CBD.

Warren WG, Osborn M, Yates A et al. · British journal of clinical pharmacology · (2026) · View on PubMed ↗

Sustainable miniaturized smartphone-coupled TLC platform for innovative cleaning validation: application to tizanidine combinations under challenging concentration ratios.

This work developed a sustainable, miniaturized smartphone-coupled thin-layer chromatography (TLC) platform for at-line pharmaceutical cleaning validation and applied it to quantify tizanidine (TZN) carryover under challenging concentration ratios in the presence of aceclofenac (ACF), ibuprofen (IBF), and paracetamol (PRC). The key finding is that the platform enables rapid, portable determination of TZN in combination matrices to support routine monitoring of cross-contamination risk. Scientifically and clinically, it provides a practical analytical tool to strengthen cleaning validation for high-risk drugs with narrow therapeutic indices and abuse potential.

Abd El-Aziz MO, Nadim AH, Monir HH et al. · Scientific reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on July 29, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.